JSON
Mowbray SL, Kathiravan MK, Pandey AA, Odell LR
Molecules 19 (9) 13161-13176 [2014-08-26; online 2014-08-26]
Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. Globally, tuberculosis is second only to AIDS in mortality and the disease is responsible for over 1.3 million deaths each year. The impractically long treatment schedules (generally 6-9 months) and unpleasant side effects of the current drugs often lead to poor patient compliance, which in turn has resulted in the emergence of multi-, extensively- and totally-drug resistant strains. The development of new classes of anti-tuberculosis drugs and new drug targets is of global importance, since attacking the bacterium using multiple strategies provides the best means to prevent resistance. This review presents an overview of the various strategies and compounds utilized to inhibit glutamine synthetase, a promising target for the development of drugs for TB therapy.
PubMed 25162957
DOI 10.3390/molecules190913161
Crossref 10.3390/molecules190913161
pii: molecules190913161